A New IDEA in Adjuvant Chemotherapy for Colon Cancer
A partir des données de 6 essais de phase III comparant l'efficacité d'une chimiothérapie adjuvante de type FOLFOX (fluorouracile, leucovorine, oxaliplatine) et de type CAPOX (capécitabine et oxaliplatine) chez des patients atteints d'un cancer du côlon de stade III, cette étude compare l'efficacité, du point de vue de la survie sans maladie à 3 ans, de deux durées d'administration du traitement (3 ou 6 mois)
Prospective, randomized trials have clearly established that the relative risk of tumor recurrence or death from colon cancer is approximately 30% lower among patients who receive adjuvant fluorouracil-based chemotherapy administered for 6 months than among those who undergo surgery alone, with the benefits confined mainly to patients with stage III (lymph-node–positive) disease.1-3 The absolute improvement in the 5-year rate of disease-free survival with chemotherapy, as compared with no adjuvant therapy, is approximately 7 to 10 percentage points. The addition of the drug oxaliplatin to fluorouracil plus leucovorin in a regimen commonly known as FOLFOX results in a further improvement in . . .